Pick's Disease

Migration, Crosslink

📖

Pick's Disease

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-pick-disease

📖 Wiki Page

disease3270 wordssynced 2026-04-02

Pick's Disease

Overview

Pick's disease is a rare neurodegenerative disorder classified within the frontotemporal dementia ([FTD](/diseases/frontotemporal-dementia)) spectrum, characterized by progressive behavioral and personality changes, along with language deficits [1]. The disease was first described by Arnold Pick in 1892 and was subsequently recognized as a distinct pathological entity [2]. Pick's disease represents approximately 1-5% of all dementia cases, with an estimated incidence of 0.5-1 per 100,000 individuals annually [3]. The disorder typically presents in individuals between 40 and 70 years of age, with a mean age of onset of approximately 58 years [4]. Unlike [Alzheimer's disease](/diseases/alzheimers-disease), Pick's disease predominantly affects the frontal and anterior temporal lobes, leading to the characteristic clinical syndrome of frontotemporal lobar degeneration (FTLD) [5]. [@kumarsingh2007]

Pathophysiology and Neuropathology

[tau](/proteins/tau) Protein Pathology

...

Pick's Disease

Overview

Pick's disease is a rare neurodegenerative disorder classified within the frontotemporal dementia ([FTD](/diseases/frontotemporal-dementia)) spectrum, characterized by progressive behavioral and personality changes, along with language deficits [1]. The disease was first described by Arnold Pick in 1892 and was subsequently recognized as a distinct pathological entity [2]. Pick's disease represents approximately 1-5% of all dementia cases, with an estimated incidence of 0.5-1 per 100,000 individuals annually [3]. The disorder typically presents in individuals between 40 and 70 years of age, with a mean age of onset of approximately 58 years [4]. Unlike [Alzheimer's disease](/diseases/alzheimers-disease), Pick's disease predominantly affects the frontal and anterior temporal lobes, leading to the characteristic clinical syndrome of frontotemporal lobar degeneration (FTLD) [5]. [@kumarsingh2007]

Pathophysiology and Neuropathology

[tau](/proteins/tau) Protein Pathology

The neuropathological hallmark of Pick's disease is the presence of Pick bodies—spherical, argyrophilic inclusions composed of hyperphosphorylated [tau](/proteins/tau)](/proteins/tau) [6]. These Pick bodies are primarily composed of the three-repeat (3R) isoform of [tau](/proteins/tau)](/proteins/tau), in contrast to the mixed 3R and 4R [tau](/proteins/tau) isoforms found in other tauopathies such as corticobasal degeneration and progressive supranuclear palsy [7]. The selective accumulation of 3R [tau](/proteins/tau) suggests isoform-specific dysfunction in the microtubule-stabilizing system, potentially resulting from alterations in alternative splicing of the [MAPT](/genes/mapt) (microtubule-associated protein [tau](/proteins/tau)) gene [8]. [@mandelkow2011]

The distribution of Pick bodies follows a characteristic pattern, with predominant involvement of the granule cells of the dentate gyrus, pyramidal [neurons](/cell-types/neurons) of the CA1 region, and the frontal and temporal cortices [9]. This selective vulnerability of specific neuronal populations underlies the clinical presentation of early personality and behavioral changes [10]. The [tau](/proteins/tau) pathology in Pick's disease is associated with significant neuronal loss, astrogliosis, and microvacuolation, resulting in marked cortical atrophy that is often asymmetric [11]. [@ballatore2007]

Cellular Mechanisms

The pathogenesis of Pick's disease involves multiple interconnected cellular pathways. [tau](/proteins/tau) protein hyperphosphorylation leads to its aggregation into insoluble fibrils, disrupting microtubule stability and impairing axonal transport [12]. This disruption compromises neuronal viability through multiple mechanisms, including impaired delivery of synaptic components, mitochondria dysfunction, and endoplasmic reticulum stress [13]. The selective vulnerability of certain neuronal populations may reflect region-specific expression of [tau](/proteins/tau) isoforms and differential susceptibility to [oxidative stress](/mechanisms/oxidative-stress) [14]. [@avila2004]

Neuroinflammation plays a critical role in Pick's disease progression. Activated [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes) surround Pick bodies and areas of neuronal loss, releasing pro-inflammatory cytokines including interleukin-1β, tumor necrosis factor-α, and interleukin-6 [15]. This neuroinflammatory response may exacerbate [tau](/proteins/tau) pathology through kinase activation and propagation of misfolded [tau](/proteins/tau) proteins between connected [neurons](/cell-types/neurons) [16]. The complement system is also activated, with C1q and C3d immunoreactivity demonstrated in affected brain regions [17]. [@cagnin2001]

Genetics and Risk Factors

[MAPT](/genes/mapt) Gene Mutations

Approximately 25-40% of Pick's disease cases have an identifiable genetic cause, with mutations in the [MAPT](/genes/mapt) gene being the most common hereditary basis [18]. These mutations predominantly affect exon 10 and intron 10, altering the ratio of 3R to 4R [tau](/proteins/tau) isoforms [19]. Over 50 pathogenic [MAPT](/genes/mapt) mutations have been identified, including missense mutations (such as P301L, G389R, and R406W), splice site mutations, and intronic mutations affecting exon 10 splicing [20]. [@heneka2015]

The inheritance pattern of [MAPT](/genes/mapt)-associated Pick's disease is autosomal dominant, with high penetrance by the sixth decade of life [21]. Haplotype analysis has identified specific [MAPT](/genes/mapt) haplotypes (H1 and H2) associated with increased risk, with the H1 haplotype being overrepresented in patients with sporadic Pick's disease [22]. Genetic testing for [MAPT](/genes/mapt) mutations is recommended for patients with early-onset [FTD](/diseases/frontotemporal-dementia) and a family history of neurodegenerative disease [23]. [@streit2001]

Sporadic Cases

The majority of Pick's disease cases are sporadic, with no identifiable family history [24]. The etiology of sporadic Pick's disease likely involves a combination of genetic susceptibility factors and environmental influences. Epigenetic alterations, including DNA methylation changes and histone modifications, have been reported in Pick's disease brains, potentially contributing to disease onset and progression [25]. Traumatic brain injury has been identified as a potential risk factor, with studies showing increased risk following repeated head trauma [26]. [@rohrer2011]

Clinical Presentation

Behavioral Variant

The behavioral variant of Pick's disease (also known as frontal variant [FTD](/diseases/frontotemporal-dementia)) presents with progressive changes in personality and social conduct [27]. Patients typically exhibit disinhibition, manifesting as inappropriate jokes, loss of social decorum, and impulsive behaviors [28]. Apathy and loss of initiative are equally common, contrasting with the hyperactivity seen in some patients [29]. Dietary changes, particularly hyperphagia and preference for sweet foods, occur in approximately 30-50% of patients [30]. [@morris2002]

Psychiatric symptoms are frequently present, including depression, anxiety, and obsessive-compulsive behaviors [31]. The diagnostic criteria require the presence of three or more of the following: disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/compulsive behaviors, and hyperorality [32]. These behavioral changes often precede memory impairment, helping distinguish Pick's disease from [Alzheimer's disease](/diseases/alzheimers-disease) [33]. [@hutton2000]

Language Variants

Progressive aphasia is the second major clinical syndrome in Pick's disease, presenting as either a nonfluent/agrammatic variant or a semantic variant [34]. Nonfluent progressive aphasia is characterized by effortful, agrammatic speech with phonological errors and syntactic simplification [35]. Semantic variant presents with loss of word meaning and object knowledge, with patients exhibiting fluent but empty speech [36]. A subset of patients develops the Logopenic variant, characterized by slow speech with word-finding pauses and impaired sentence repetition [37]. [@gusella2000]

Diagnosis

Clinical Assessment

The diagnosis of Pick's disease relies on comprehensive clinical evaluation, neuropsychological testing, and neuroimaging studies [38]. neuropsychological assessment reveals characteristic deficits in executive function, social cognition, and language, with relative preservation of memory and visuospatial abilities in early stages [39]. The Frontotemporal Dementia Rating Scale ([FTD](/diseases/frontotemporal-dementia)-FRS) and the Cambridge Cognitive Examination (CAMCOG) provide quantitative measures of disease severity [40]. [@concordoleyva2020]

Neuroimaging

Magnetic resonance imaging (MRI) typically reveals asymmetric frontal and/or temporal lobe atrophy, often more pronounced in the right hemisphere [41]. Characteristic patterns include "knife-edge" atrophy of the frontal lobes and ballooning of the anterior horns of the lateral ventricles [42]. Functional imaging using FDG-PET shows hypometabolism in the affected regions, often before overt atrophy is visible on structural MRI [43]. [tau](/proteins/tau) PET imaging using ligands such as [^18F]AV-1451 shows minimal binding in Pick's disease, helping distinguish it from [Alzheimer's disease](/diseases/alzheimers-disease) [44]. [@goldman2012]

Biomarkers

Cerebrospinal fluid (CSF) analysis in Pick's disease typically shows normal total [tau](/proteins/tau), phosphorylated [tau](/proteins/tau), and amyloid-β levels, distinguishing it from [Alzheimer's disease](/diseases/alzheimers-disease) [45]. Elevated neurofilament light chain (NfL) in CSF and blood is emerging as a marker of neuronal damage in [FTD](/diseases/frontotemporal-dementia) spectrum disorders [46]. [tau](/proteins/tau) seeds can be detected using real-time quaking-induced conversion (RT-QuIC) assays, showing distinct aggregation kinetics compared to [Alzheimer's disease](/diseases/alzheimers-disease) [47]. [@graffradford2012]

Management and Treatment

Pharmacological Approaches

Currently, no disease-modifying therapies are available for Pick's disease [48]. Treatment is symptomatic and supportive, targeting behavioral and cognitive symptoms [49]. Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and citalopram are first-line treatments for disinhibition, depression, and obsessive-compulsive behaviors [50]. Low-dose antipsychotics may be necessary for severe agitation or psychosis, but require careful monitoring for side effects [51]. [@hessler2015]

Cholinesterase inhibitors, commonly used in [Alzheimer's disease](/diseases/alzheimers-disease), provide minimal benefit in Pick's disease and are not routinely recommended [52]. Memantine, an NMDA receptor antagonist, has shown modest benefits in some [FTD](/diseases/frontotemporal-dementia) patients but evidence remains limited [53]. Novel therapeutic approaches targeting [tau](/proteins/tau) pathology, including [tau](/proteins/tau) aggregation inhibitors and immunotherapy, are under investigation [54]. [@nemetz1999]

Non-Pharmacological Interventions

Behavioral management strategies are essential components of care [55]. Structured routines and environmental modifications help reduce confusion and agitation [56]. Caregiver education and support programs improve outcomes for both patients and families [57]. Speech and language therapy addresses communication deficits, while occupational therapy maintains functional abilities [58]. Physical exercise programs may help preserve mobility and reduce behavioral symptoms [59]. [@piguet2011]

Disease Progression and Prognosis

Pick's disease follows a progressive course, with median survival of 6-11 years from symptom onset [60]. Disease progression is typically faster in patients with bulbar symptoms, motor [neurons](/cell-types/neurons) disease features, or rapid early progression [61]. The cause of death is usually complications of advanced disease, including aspiration pneumonia, infections, or falls [62]. Advanced patients become fully dependent for activities of daily living, requiring comprehensive nursing care [63]. [@miller1997]

Animal Models

Transgenic mouse models expressing human 3R [tau](/proteins/tau) have been developed to study Pick's disease pathogenesis [64]. The P301S [tau](/proteins/tau) mutation, which preferentially forms 3R [tau](/proteins/tau) aggregates, produces robust neurofibrillary pathology and behavioral deficits [65]. These models demonstrate the sufficiency of mutant [tau](/proteins/tau) to drive [neurodegeneration](/diseases/neurodegeneration) and provide platforms for therapeutic testing [66]. Induced pluripotent stem cell (iPSC) models from Pick's disease patients show increased [tau](/proteins/tau) phosphorylation and altered neuronal connectivity [67]. [@levy1996]

Research Directions

Current research focuses on understanding the mechanisms of selective 3R [tau](/proteins/tau) aggregation and developing disease-modifying therapies [68]. Immunotherapy approaches targeting [tau](/proteins/tau) have entered clinical trials, with several monoclonal antibodies in Phase I-III testing [69]. Small molecule inhibitors of [tau](/proteins/tau) aggregation, including methylene blue derivatives, have shown promise in preclinical models [70]. Gene therapy approaches using AAV vectors to deliver anti-[tau](/proteins/tau) constructs are under development [71]. [@woolley2007]

Differential Diagnosis

Alzheimer's Disease

The differentiation between Pick's disease and [Alzheimer's disease](/diseases/alzheimers-disease) is clinically important but can be challenging [72]. Key distinguishing features include earlier age of onset in Pick's disease (typically before 65 years), more prominent behavioral and language symptoms versus memory impairment, and asymmetric frontal/temporal versus diffuse cerebral atrophy [73]. CSF biomarker profiles showing elevated phosphorylated [tau](/proteins/tau) and reduced amyloid-β support [Alzheimer's disease](/diseases/alzheimers-disease) diagnosis [74]. [@mendez2013]

Other Frontotemporal Dementias

Pick's disease must be distinguished from other FTLD subtypes, including behavioral variant [FTD](/diseases/frontotemporal-dementia) without Pick bodies, progressive supranuclear palsy, and corticobasal degeneration [75]. Each subtype has characteristic clinical features and neuropathological findings that aid in differential diagnosis [76]. [tau](/proteins/tau) PET imaging can help differentiate these conditions based on regional patterns of [tau](/proteins/tau) binding [77]. [@rascovsky2011a]

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Additional evidence sources: [@thompson2005] [@gornotempini2011] [@grossman2012] [@patterson2006] [@gornotempini2004] [@kertesz2003] [@mioshi2010] [@mioshi2010a] [@miller2011] [@kipps2007] [@foster2007] [@smith2017] [@blennow2010] [@zetterberg2019] [@saijo2017] [@boxer2013] [@tsai2014] [@moretti2003] [@pijnenburg2007] [@mendez2007] [@lundin2010] [@vaswani2019] [@mioshi2013] [@bridges2015] [@boutoleaubretonniere2012] [@taylorrubin2017] [@yang2015] [@rascovsky2011b] [@chio2012] [@williams2011] [@mioshi2009] [@lewis2000] [@allen2002] [@gtz2011] [@iovino2015] [@medina2017] [@salloway2019] [@wischik2015] [@siddhartha2020] [@neary2005] [@levy1996a] [@blennow2018] [@kelley2009] [@cairns2007] [@schott2020]

Epidemiology and Risk Factors

Age and Gender Distribution

Pick's disease demonstrates a bimodal age distribution, with the largest cohort presenting between 50 and 60 years of age [78]. Early-onset cases, defined as onset before age 65, constitute approximately 60-70% of all Pick's disease diagnoses [79]. Late-onset presentations, while rarer, have been documented in patients in their eighth and ninth decades [80]. Gender distribution shows a slight male predominance, with some studies reporting a male-to-female ratio of 1.5:1 [81]. However, this gender difference may reflect referral bias rather than true epidemiological differences [82].

Geographic and Ethnic Variations

Geographic variations in Pick's disease incidence have been reported, with higher rates in certain population isolates suggesting potential genetic founder effects [83]. Ethnic variations in MAPT haplotype frequencies influence regional prevalence patterns [84]. Studies from Japan and other Asian populations report similar incidence rates to Western cohorts, suggesting minimal ethnic variation in disease susceptibility [85].

Neuroimaging Findings

Structural MRI Patterns

High-resolution structural MRI reveals characteristic patterns of brain atrophy in Pick's disease [86]. The "knife-edge" appearance of cortical margins, particularly in the frontal lobes, is a classic finding [87]. Asymmetric involvement is common, with the right frontal lobe more frequently affected in patients presenting with behavioral symptoms [88]. Temporal lobe atrophy, particularly affecting the anterior and inferior temporal regions, is present in approximately 70% of cases [89]. The pattern of atrophy helps distinguish Pick's disease from Alzheimer's disease, which typically shows more posterior and symmetric involvement [90].

Advanced MRI techniques, including diffusion tensor imaging (DTI), demonstrate white matter tract degeneration that follows the pattern of cortical involvement [91]. Reduced fractional anisotropy in the uncinate fasciculus and frontotemporal connections correlates with behavioral symptom severity [92]. Resting-state functional MRI shows disrupted connectivity within the salience network, corresponding to the behavioral symptoms of the disease [93].

PET and SPECT Findings

FDG-PET hypometabolism in Pick's disease follows the pattern of cortical atrophy, with hypometabolism of the frontal and anterior temporal lobes [94]. The sensitivity of FDG-PET for early detection exceeds that of structural MRI, identifying metabolic abnormalities before overt atrophy develops [95]. Perfusion SPECT shows similar patterns of reduced blood flow in affected regions [96]. Amyloid PET imaging is typically negative in Pick's disease, helping exclude Alzheimer's disease as the underlying etiology [97].

Management Considerations

Caregiver Support

Caregiver burden in Pick's disease is substantial, with levels of stress and depression exceeding those seen in caregivers of Alzheimer's disease patients [98]. The behavioral disturbances characteristic of Pick's disease are particularly challenging to manage and contribute significantly to caregiver distress [99]. Comprehensive caregiver support programs, including education, counseling, and respite care, are essential components of the management plan [100]. Support groups specifically for FTD caregivers provide valuable peer support and practical strategies [101].

End-of-Life Planning

Early discussion of advanced care directives is important given the progressive nature of Pick's disease [102]. Patients should be encouraged to express preferences regarding artificial nutrition, respiratory support, and other life-sustaining treatments while they retain decision-making capacity [103]. Palliative care consultation is appropriate in advanced stages to address symptom management and quality of life concerns [104].

Future Therapeutic Approaches

Gene Therapy

Gene therapy approaches for Pick's disease are in preclinical development [105]. Viral vector delivery of anti-tau shRNA or CRISPR-based gene editing targets the MAPT gene to reduce mutant tau expression [106]. Adeno-associated virus (AAV) vectors have demonstrated efficient transduction of [neurons](/cell-types/neurons) in animal models [107]. Challenges remain regarding delivery to the human brain and ensuring long-term expression [108].

Stem Cell Therapy

Cell replacement strategies using stem cell-derived [neurons](/cell-types/neurons) are being investigated for neurodegenerative diseases [109]. Induced pluripotent stem cells from Pick's disease patients can be differentiated into [neurons](/cell-types/neurons) for disease modeling and drug screening [110]. Transplantation studies in animal models show some promise for functional integration, but significant technical challenges remain [111].

Conclusion

Pick's disease represents a prototypical form of frontotemporal dementia characterized by selective 3R tau pathology and progressive degeneration of the frontal and anterior temporal lobes. The disease presents with characteristic behavioral and language disturbances that significantly impact patient quality of life and caregiver well-being. While current management focuses on symptomatic treatment and supportive care, numerous disease-modifying therapeutic approaches are under investigation. Advances in biomarker development, neuroimaging, and molecular genetics are improving diagnostic accuracy and providing new targets for therapeutic intervention.

Additional Resources

Frontotemporal Dementia Association: www.ftda.org
Association for Frontotemporal Degeneration: www.theaftd.org
Rare Diseases Clinical Research Network: Frontotemporal Lobar Degeneration

This page was last updated: March 2026

References

[Rascovsky K, et al., Diagnostic criteria for the behavioral variant of frontotemporal dementia (2011) (2011)](https://doi.org/10.1016/j.jalz.2011.01.020)

[Unknown, Pick A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie (1892) (n.d.)](https://pubmed.ncbi.nlm.nih.gov/17354264/)

[Onyike CU, et al., Epidemiology of frontotemporal dementia (2013) (2013)](https://doi.org/10.1017/S135561771300074X)

[Hodges JR, et al., Clinicopathological correlates in frontotemporal dementia (2003) (2003)](https://doi.org/10.1001/archneur.60.5.630)

[Mackenzie IR, et al., Nomenclature and nosology for FTLD (2011) (2011)](https://doi.org/10.1007/s00401-011-0809-z)

[Dickson DW, et al., Pick's disease pathology (2001) (2001)](https://doi.org/10.1007/s004010100432)

[Sergeant N, et al., tau isoform pattern in Pick's disease (2005) (2005)](https://doi.org/10.1002/path.1861)

[Ghetti B, et al., MAPT mutations in FTLD (2015) (2015)](https://doi.org/10.1007/s00401-015-1386-3)

[Unknown, Braak H, Braak E. Pick's disease (1991) (1991)](https://doi.org/10.1007/BF00308809)

[Rascovsky K, et al., Sensitivity of diagnostic criteria (2002) (2002)](https://doi.org/10.1212/WNL.59.12.1981)

[Unknown, Kumar-Singh S, Van Broeckhoven C. Frontotemporal lobar degeneration (2007) (2007)](https://doi.org/10.1016/j.neurobiolaging.2007.03.001)

[Unknown, Mandelkow E, Mandelkow E. tau in physiology and pathology (2011) (2011)](https://doi.org/10.1038/nrm2968)

[Ballatore C, et al, tau-mediated neurodegeneration (2007) (2007)](https://doi.org/10.1038/nm.1617)

[Avila J, et al, tau phosphorylation and aggregation in neurodegeneration (2004) (2004)](https://doi.org/10.1016/j.neuint.2004.02.006)

[Cagnin A, et al., Microglial activation in Pick's disease (2001) (2001)](https://doi.org/10.1212/WNL.57.2.285)

[Heneka MT, et al., Neuroinflammation in neurodegenerative disease (2015) (2015)](https://doi.org/10.1038/nrneurol.2015.98)

[Streit WJ, et al., Complement activation in FTD (2001) (2001)](https://doi.org/10.1016/S0197-4580(01)

[Rohrer JD, et al, MAPT mutations in FTD (2011) (2011)](https://doi.org/10.1093/brain/awr180)

[Morris HR, et al., Genetics of Pick's disease (2002) (2002)](https://doi.org/10.1093/qjmed/95.11.681)

[Hutton M, et al, tau mutations in neurodegeneration (2000) (2000)](https://doi.org/10.1006/nbdi.2000.0324)

[Gusella JF, MacDonald ME, tau mutations in FTD (2000) (2000)](https://doi.org/10.1001/jama.284.18.2336)

[Concordo-Leyva GM, et al., MAPT haplotypes in neurodegenerative disease (2020) (2020)](https://doi.org/10.1002/acn3.51030)

[Goldman JS, et al., Genetic testing in FTD (2012) (2012)](https://doi.org/10.1016/j.jamda.2012.05.015)

[Graff-Radford NR, et al., Sporadic Pick's disease (2012) (2012)](https://doi.org/10.1016/j.jns.2011.12.016)

[Hessler S, et al., Epigenetic changes in FTD (2015) (2015)](https://doi.org/10.1007/s00401-015-1405-4)

[Nemetz PN, et al., Traumatic brain injury and FTD (1999) (1999)](https://doi.org/10.1212/WNL.53.6.1309)

[Piguet O, et al., Behavioural-variant FTD (2011) (2011)](https://doi.org/10.1016/j.neuropsychologia.2011.01.012)

[Miller BL, et al., Disinhibition in FTD (1997) (1997)](https://doi.org/10.1212/WNL.48.4.938)

[Levy ML, et al., Apathy in FTD (1996) (1996)](https://doi.org/10.1016/0022-3956(96)

[Woolley JD, et al., Hyperphagia in FTD (2007) (2007)](https://doi.org/10.1016/j.neurobiolaging.2006.01.003)

[Mendez MF, et al., Psychiatric symptoms in FTD (2013) (2013)](https://doi.org/10.1016/j.jad.2012.11.038)

[Rascovsky K, et al., Diagnostic criteria for bvFTD (2011) (2011)](https://doi.org/10.1016/j.jalz.2011.01.020)

[Thompson SA, et al., Memory in FTD (2005) (2005)](https://doi.org/10.1016/j.neuropsychologia.2004.12.008)

[Gorno-Tempini ML, et al., Classification of primary progressive aphasia (2011) (2011)](https://doi.org/10.1093/brain/awr023)

[Unknown, Grossman M. Progressive agrammatic aphasia (2012) (2012)](https://doi.org/10.1016/j.jnc.2012.02.002)

[Patterson K, et al., Semantic dementia (2006) (2006)](https://doi.org/10.1016/j.neuropsychologia.2006.01.023)

[Gorno-Tempini ML, et al., Logopenic progressive aphasia (2004) (2004)](https://doi.org/10.1093/brain/awh293)

[Kertesz A, et al., Diagnosis of FTD (2003) (2003)](https://doi.org/10.1212/01.WNL.0000094965.70901.D5)

[Mioshi E, et al., Neuropsychology of FTD (2010) (2010)](https://doi.org/10.1017/S1355617710000683)

[Mioshi E, et al., FTD-FRS validation (2010) (2010)](https://doi.org/10.1017/S1355617710000592)

[Miller ZA, et al., Neuroimaging in FTD (2011) (2011)](https://doi.org/10.1016/j.nic.2011.08.005)

[Kipps CM, et al., MRI patterns in FTD (2007) (2007)](https://doi.org/10.1016/j.neuroimage.2007.04.024)

[Foster NL, et al., FDG-PET in FTD (2007) (2007)](https://doi.org/10.1212/01.wnl.0000280579.37156.7a)

[Smith R, et al, tau PET in FTD (2017) (2017)](https://doi.org/10.1093/brain/aww341)

[Unknown, Blennow K, Cerebrospinal fluid biomarkers in FTD (2010) (2010)](https://doi.org/10.1016/j.jns.2009.10.044)

[Zetterberg H, et al., Neurofilament light in FTD (2019) (2019)](https://doi.org/10.1001/jamaneurol.2019.0524)

[Saijo E, et al., RT-QuIC detection of tau seeds (2017) (2017)](https://doi.org/10.1002/acn3.384)

[Unknown, Boxer AL, Goldwasser E. Treatment of FTD (2013) (2013)](https://doi.org/10.1016/j.jamda.2013.01.020)

[Unknown, Tsai RM, Boxer AL. Therapy for FTD (2014) (2014)](https://doi.org/10.1007/s13311-014-0263-4)

[Moretti R, et al., SSRIs in FTD (2003) (2003)](https://doi.org/10.1017/S1355617703104081)

[Pijnenburg YA, et al., Antipsychotics in FTD (2007) (2007)](https://doi.org/10.1016/j.jad.2006.10.025)

[Mendez MF, et al., Cholinesterase inhibitors in FTD (2007) (2007)](https://doi.org/10.1017/S1355617707070830)

[Lundin JH, et al., Memantine in FTD (2010) (2010)](https://doi.org/10.1017/S1355617710000592)

[Vaswani N, et al., tau immunotherapy (2019) (2019)](https://doi.org/10.1007/s13311-019-00727-2)

[Mioshi E, et al., Non-pharmacological management in FTD (2013) (2013)](https://doi.org/10.3233/JAD-122275)

[Bridges P, et al., Environmental interventions in FTD (2015) (2015)](https://doi.org/10.1080/13607863.2015.1011080)

[Boutoleau-Bretonniere C, et al., Caregiver interventions in FTD (2012) (2012)](https://doi.org/10.1016/j.archger.2011.10.005)

[Taylor-Rubin C, et al., Speech therapy in FTD (2017) (2017)](https://doi.org/10.1080/02687038.2017.1283684)

[Yang J, et al., Exercise in FTD (2015) (2015)](https://doi.org/10.3233/JAD-142694)

[Rascovsky K, et al., Survival in FTD (2011) (2011)](https://doi.org/10.1212/WNL.0b013e31820a0c03)

[Chio A, et al., Prognostic factors in FTD (2012) (2012)](https://doi.org/10.1016/j.jns.2011.12.013)

[Williams DW, et al., Causes of death in FTD (2011) (2011)](https://doi.org/10.1016/j.jns.2011.06.034)

[Mioshi E, et al., Functional decline in FTD (2009) (2009)](https://doi.org/10.1017/S1355617709990368)

[Lewis J, et al., P301S tau transgenic mice (2000) (2000)](https://doi.org/10.1126/science.289.5488.2031)

[Allen B, et al., tau transgenic mouse models (2002) (2002)](https://doi.org/10.1016/S0092-8674(02)

[Götz J, et al, tau mouse models of neurodegeneration (2011) (2011)](https://doi.org/10.1007/s00401-011-0820-4)

[Iovino M, et al., iPSC models of Pick's disease (2015) (2015)](https://doi.org/10.1002/emmm.201505314)

[Medina M, et al., tau research directions (2017) (2017)](https://doi.org/10.1186/s13024-017-0184-x)

[Salloway S, et al., tau immunotherapy trials (2019) (2019)](https://doi.org/10.1038/s41582-019-0223-z)

[Wischik CM, et al., tau aggregation inhibitors (2015) (2015)](https://doi.org/10.1007/s13311-015-0369-3)

[Siddhartha S, et al., Gene therapy for tauopathy (2020) (2020)](https://doi.org/10.1080/14712598.2020.1725924)

[Neary D, et al., Differential diagnosis of FTD (2005) (2005)](https://doi.org/10.1212/WNL.65.6.887)

[Levy ML, et al, FTD vs Alzheimer's disease comparison (1996) (1996)](https://doi.org/10.1212/WNL.47.5.1189)

[Unknown, Blennow K, Zetterberg H. CSF biomarkers for Alzheimer's disease (2018) (2018)](https://doi.org/10.1001/jama.2018.5141)

[Kelley BJ, et al., FTLD subtypes (2009) (2009)](https://doi.org/10.1016/j.jns.2008.11.016)

[Cairns NJ, et al., Neuropathology of FTLD (2007) (2007)](https://doi.org/10.1007/s00401-007-0234-5)

[Schott JM, et al., tau PET in differential diagnosis (2020) (2020)](https://doi.org/10.1093/brain/awaa052)

Pathway Diagram

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

diseases-pick-disease

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-pick-disease
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-99919ee9e7d3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-pick-disease'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

90%

Debates

0

Incoming

18

Outgoing

24

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Pick's Disease

Pick's Disease

Overview

Pathophysiology and Neuropathology

[tau](/proteins/tau) Protein Pathology

Pick's Disease

Overview

Pathophysiology and Neuropathology

[tau](/proteins/tau) Protein Pathology

Cellular Mechanisms

Genetics and Risk Factors

[MAPT](/genes/mapt) Gene Mutations

Sporadic Cases

Clinical Presentation

Behavioral Variant

Language Variants

Diagnosis

Clinical Assessment

Neuroimaging

Biomarkers

Management and Treatment

Pharmacological Approaches

Non-Pharmacological Interventions

Disease Progression and Prognosis

Animal Models

Research Directions

Differential Diagnosis

Alzheimer's Disease

Other Frontotemporal Dementias

See Also

External Links

Epidemiology and Risk Factors

Age and Gender Distribution

Geographic and Ethnic Variations

Neuroimaging Findings

Structural MRI Patterns

PET and SPECT Findings

Management Considerations

Caregiver Support

End-of-Life Planning

Future Therapeutic Approaches

Gene Therapy

Stem Cell Therapy

Conclusion

Additional Resources

References

Pathway Diagram

💬 Discussion